of India, has led to the release of these three products,” said Sushil Suri. “With a focus on new molecules, new patented processes, we now look forward towards investing more in our R and D …

More Morepen Labs adds three new drugs – Rivaroxaban, Vildagliptin and UDCA to its API Portfolio Videos